605 related articles for article (PubMed ID: 19424970)
1. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
Wittenbrink M; Spreu J; Steinle A
Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
[TBL] [Abstract][Full Text] [Related]
2. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
3. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
4. Four novel ULBP splice variants are ligands for human NKG2D.
Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
[TBL] [Abstract][Full Text] [Related]
5. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
6. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein.
Welte SA; Sinzger C; Lutz SZ; Singh-Jasuja H; Sampaio KL; Eknigk U; Rammensee HG; Steinle A
Eur J Immunol; 2003 Jan; 33(1):194-203. PubMed ID: 12594848
[TBL] [Abstract][Full Text] [Related]
7. Induction of NKG2D ligands on human dendritic cells by TLR ligand stimulation and RNA virus infection.
Ebihara T; Masuda H; Akazawa T; Shingai M; Kikuta H; Ariga T; Matsumoto M; Seya T
Int Immunol; 2007 Oct; 19(10):1145-55. PubMed ID: 17878262
[TBL] [Abstract][Full Text] [Related]
8. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
9. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142.
Chalupny NJ; Rein-Weston A; Dosch S; Cosman D
Biochem Biophys Res Commun; 2006 Jul; 346(1):175-81. PubMed ID: 16750166
[TBL] [Abstract][Full Text] [Related]
11. Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity.
Dunn C; Chalupny NJ; Sutherland CL; Dosch S; Sivakumar PV; Johnson DC; Cosman D
J Exp Med; 2003 Jun; 197(11):1427-39. PubMed ID: 12782710
[TBL] [Abstract][Full Text] [Related]
12. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
13. NKG2D and Related Immunoreceptors.
Strong RK; McFarland BJ
Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
[TBL] [Abstract][Full Text] [Related]
14. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity.
Cao W; Xi X; Hao Z; Li W; Kong Y; Cui L; Ma C; Ba D; He W
J Biol Chem; 2007 Jun; 282(26):18922-8. PubMed ID: 17470428
[TBL] [Abstract][Full Text] [Related]
15. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy.
Park MJ; Bae JH; Chung JS; Kim SH; Kang CD
Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289
[TBL] [Abstract][Full Text] [Related]
16. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
17. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
18. The inhibitory effects of synthetic short peptides, mimicking MICA and targeting at NKG2D receptors, on function of NK cells.
Zhang B; Wei H; Zheng X; Zhang J; Sun R; Tian Z
Peptides; 2005 Mar; 26(3):405-12. PubMed ID: 15652646
[TBL] [Abstract][Full Text] [Related]
19. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway.
Le Maux Chansac B; Missé D; Richon C; Vergnon I; Kubin M; Soria JC; Moretta A; Chouaib S; Mami-Chouaib F
Int Immunol; 2008 Jul; 20(7):801-10. PubMed ID: 18441340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]